As part of the agreement, Cephalon Australia will humanize the antibodies utilizing their proprietary technology and carry out all development and scientific work related to the product candidate. In early-stage development, Innate Immune demonstrated that blocking the activation of natural killer T cells using the antibody was effective for the treatment of asthma and SLE in preclinical pet models. The financial terms of the licensing agreement were not disclosed.D., Ph. D. ‘We anticipate Cephalon Australia’s further development of the exciting product candidate which has the potential to handle important medical needs.’.. Cephalon Australia granted exclusive license to build up Innate Immune’s antibodies for treatment of asthma, SLE Innate Immune, Inc., a privately held biotechnology business, today announced that it offers granted to Cephalon Australia Pty Ltd an exclusive permit to patents for the development of it is antibodies for the treatment of asthma and systemic lupus erythematosis .The findings, believed to be one of the initial culled from a nationwide sample of people diagnosed with different cancers, mirror results of cancer-related memory space impairment in smaller research of certain cancers, such as for example breast and prostate cancers. Results were presented at the 3rd AACR Meeting on The Technology of Cancer Wellness Disparities. ‘The findings show that memory impairment in cancer individuals is a national issue that we must pay special attention to,’ said Pascal Jean-Pierre, Ph.D., M.P.H., associate professor at the University of Miami Miller School of Medicine, division of pediatrics, and the Sylvester Comprehensive Cancer Center.